Immunotherapy is a form of helping the body’s immune system to identify cancer cells as foreign. Once the body can recognise the cancer cells, the immune system can mount reaction against these cells, thus hindering the growth and development of a tumour.
The technology was developed at the Bill Walsh Translational Cancer Research Laboratory, part of the Kolling Institute of Medical Research at Royal North Shore Hospital in Sydney. Regeneus has secured the exclusive worldwide rights to the human and animal applications of the therapeutic cancer vaccine technology.
Regeneus is currently looking to out-license RGSH4K to strategic partners.